ArticleBMC women's health2025
Sequential therapy of dienogest following relugolix for adenomyosis and impact on symptoms and serum CA125 levels: a case series.
Article in BMC women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Treatment selection for adenomyosis based on imaging findings and patient characteristics.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Review
- Impact of adenomyosis on pregnancy outcomes following frozen embryo transfer: development and validation of a single-center clinical predictive model.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenomyosis, characterized by endometrial tissue within the uterine muscle, often presents with severe pelvic pain and menorrhagia. This case series demonstrates the efficacy of sequential therapy involving relugolix followed by dienogest in managing adenomyosis. CASE PRESENTATION: In five patients with adenomyosis, the gonadotropin-releasing hormone antagonist relugolix initially mitigated symptoms and reduced the levels of serum CA125, a marker associated with disease activity. After six months of relugolix, patients were transitioned to dienogest. This sequential approach maintained symptom relief and further stabilized CA125 levels.
conclusionsOur findings demonstrate that sequential therapy provides effective symptom management and long-term disease control. Further, CA125 remains a valuable biomarker for monitoring therapeutic success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.